Fig. 1.
Tumoral CCRL2 expression is positively associated with robust anti-tumor T-cell immunity in cancer patients. (A) Overall survival rates of patients with metastatic melanoma (SKCM) from The Cancer Genome Atlas (TCGA) database with high or low CCRL2 expression as defined by the median value, n = 369. (B) Characterization of the immune cell composition in primary melanoma of TCGA datasets by CIBERSORT; data represent mean ± SEM, n = 103. (C) The heatmap showing the z-score normalized log-cpm values of signature immune gene sets based on CCRL2 expression levels. n = 103. (D) GSEA demonstrating the enrichment of signature genes of T-cell activation and IFN-γ responses in CCRL2hi tumors. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.